Mangoceuticals (NASDAQ:MGRX – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.22) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.07 million during the quarter. Mangoceuticals had a negative return on equity of 109.38% and a negative net margin of 4,536.70%.
Mangoceuticals Price Performance
Mangoceuticals stock opened at $0.41 on Wednesday. The stock has a market cap of $7.01 million, a price-to-earnings ratio of -0.16 and a beta of 2.12. Mangoceuticals has a 1 year low of $0.16 and a 1 year high of $2.75. The firm has a 50-day moving average of $0.38 and a two-hundred day moving average of $0.70.
Analyst Ratings Changes
MGRX has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Mangoceuticals to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Mangoceuticals has a consensus rating of “Sell”.
Institutional Investors Weigh In On Mangoceuticals
Several large investors have recently modified their holdings of the business. Armistice Capital LLC bought a new stake in shares of Mangoceuticals in the 4th quarter valued at about $1,137,000. Ikarian Capital LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $102,000. Jane Street Group LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $35,000. Boothbay Fund Management LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $28,000. Finally, Virtu Financial LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $25,000. Institutional investors own 56.72% of the company’s stock.
About Mangoceuticals
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.
Read More
- Five stocks we like better than Mangoceuticals
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
